Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 147


Generosity and Duration of Medicaid Expansion Waivers and Access to Care.

Tarazi WW, Bradley CJ, Harless DW, Bear HD, Sabik LM.

Am J Prev Med. 2018 Sep 14. pii: S0749-3797(18)32077-4. doi: 10.1016/j.amepre.2018.06.020. [Epub ahead of print]


Gr1-/low CD11b-/low MHCII+ myeloid cells boost T cell anti-tumor efficacy.

Payne KK, Aqbi HF, Butler SE, Graham L, Keim RC, Wan W, Idowu MO, Bear HD, Wang XY, Manjili MH.

J Leukoc Biol. 2018 Jul 9. doi: 10.1002/JLB.5A0717-276RR. [Epub ahead of print]


Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy.

Aqbi HF, Tyutyunyk-Massey L, Keim RC, Butler SE, Thekkudan T, Joshi S, Smith TM, Bandyopadhyay D, Idowu MO, Bear HD, Payne KK, Gewirtz DA, Manjili MH.

Oncotarget. 2018 Apr 24;9(31):22113-22122. doi: 10.18632/oncotarget.25197. eCollection 2018 Apr 24.


Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.

Ingle JN, Kalari KR, Wickerham DL, von Minckwitz G, Fasching PA, Furukawa Y, Mushiroda T, Goetz MP, Barman P, Carlson EE, Rastogi P, Costantino JP, Cairns J, Paik S, Bear HD, Kubo M, Wang L, Wolmark N, Weinshilboum RM.

Pharmacogenet Genomics. 2018 Jun;28(6):147-152. doi: 10.1097/FPC.0000000000000337.


Papillary lesions of the breast: To excise or observe?

Khan S, Diaz A, Archer KJ, Lehman RR, Mullins T, Cardenosa G, Bear HD.

Breast J. 2018 May;24(3):350-355. doi: 10.1111/tbj.12907. Epub 2017 Aug 27.


Impact of Medicaid disenrollment in Tennessee on breast cancer stage at diagnosis and treatment.

Tarazi WW, Bradley CJ, Bear HD, Harless DW, Sabik LM.

Cancer. 2017 Sep 1;123(17):3312-3319. doi: 10.1002/cncr.30771. Epub 2017 Jun 26.


Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.

Bear HD, Wan W, Robidoux A, Rubin P, Limentani S, White RL Jr, Granfortuna J, Hopkins JO, Oldham D, Rodriguez A, Sing AP.

J Surg Oncol. 2017 Jun;115(8):917-923. doi: 10.1002/jso.24610. Epub 2017 Apr 13.


Expansion of T Cells with Interleukin-21 for Adoptive Immunotherapy of Murine Mammary Carcinoma.

Zoon CK, Wan W, Graham L, Bear HD.

Int J Mol Sci. 2017 Jan 29;18(2). pii: E270. doi: 10.3390/ijms18020270.


Angiopoietin pathway gene expression associated with poor breast cancer survival.

Ramanathan R, Olex AL, Dozmorov M, Bear HD, Fernandez LJ, Takabe K.

Breast Cancer Res Treat. 2017 Feb;162(1):191-198. doi: 10.1007/s10549-017-4102-2. Epub 2017 Jan 6.


The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40.

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N.

Ann Surg Oncol. 2017 Jul;24(7):1853-1860. doi: 10.1245/s10434-016-5662-9. Epub 2016 Nov 18.


Modified breast cancer model for preclinical immunotherapy studies.

Katsuta E, DeMasi SC, Terracina KP, Spiegel S, Phan GQ, Bear HD, Takabe K.

J Surg Res. 2016 Aug;204(2):467-474. doi: 10.1016/j.jss.2016.06.003. Epub 2016 Jun 8.


DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.

Terracina KP, Graham LJ, Payne KK, Manjili MH, Baek A, Damle SR, Bear HD.

Cancer Immunol Immunother. 2016 Sep;65(9):1061-73. doi: 10.1007/s00262-016-1868-8. Epub 2016 Jul 14.


Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.

Payne KK, Keim RC, Graham L, Idowu MO, Wan W, Wang XY, Toor AA, Bear HD, Manjili MH.

J Leukoc Biol. 2016 Sep;100(3):625-35. doi: 10.1189/jlb.5A1215-580R. Epub 2016 Feb 29.


Medicaid expansion and access to care among cancer survivors: a baseline overview.

Tarazi WW, Bradley CJ, Harless DW, Bear HD, Sabik LM.

J Cancer Surviv. 2016 Jun;10(3):583-92. doi: 10.1007/s11764-015-0504-5. Epub 2015 Dec 11.


A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.

Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, Cormack J, Muzi JP, Pryma DA, Specht JM, Hovanessian-Larsen L, Miliziano J, Mallett S, Shields AF, Mankoff DA; ACRIN 668 Investigative Team.

J Nucl Med. 2015 Nov;56(11):1681-9. doi: 10.2967/jnumed.115.160663. Epub 2015 Sep 10.


Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N.

Lancet Oncol. 2015 Sep;16(9):1037-1048. doi: 10.1016/S1470-2045(15)00041-8. Epub 2015 Aug 10. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.


Perceived Stress Levels, Chemotherapy, Radiation Treatment and Tumor Characteristics Are Associated with a Persistent Increased Frequency of Somatic Chromosomal Instability in Women Diagnosed with Breast Cancer: A One Year Longitudinal Study.

Aboalela N, Lyon D, Elswick RK Jr, Kelly DL, Brumelle J, Bear HD, Jackson-Cook C.

PLoS One. 2015 Jul 15;10(7):e0133380. doi: 10.1371/journal.pone.0133380. eCollection 2015.


Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma.

Zoon CK, Wan W, Graham L, Bear HD.

Int J Mol Sci. 2015 Apr 20;16(4):8744-60. doi: 10.3390/ijms16048744.


Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling.

Youniss FM, Sundaresan G, Graham LJ, Wang L, Berry CR, Dewkar GK, Jose P, Bear HD, Zweit J.

PLoS One. 2014 Oct 21;9(10):e109162. doi: 10.1371/journal.pone.0109162. eCollection 2014.

Supplemental Content

Loading ...
Support Center